(R)-OR-S1 is a stereoisomer of OR-S1 and functions as a highly selective dual inhibitor of EZH1 and EZH2 methyltransferases. It induces differentiation and apoptosis in acute myeloid leukemia (AML) cells. The compound shows potential for clinical application in AML treatment, as it does not cause significant myelosuppression and allows normal hematopoiesis even after prolonged inhibition. It can be used alone or in combination with cytarabine for PRC2-targeted therapy in AML patients.